May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
24–Hour Control With the Latanoprost/Timolol Maleate Fixed Combination versus Timolol Maleate
Author Affiliations & Notes
  • A.G. Konstas
    Ophthalmology, Glaucoma Unit, AHEPA Hospital, Thessaloniki, Greece
  • S. Lake
    Ophthalmology, Glaucoma Unit, AHEPA Hospital, Thessaloniki, Greece
  • A.I. Economou
    Ophthalmology, Glaucoma Unit, AHEPA Hospital, Thessaloniki, Greece
  • K. Kaltsos
    Ophthalmology, Glaucoma Unit, AHEPA Hospital, Thessaloniki, Greece
  • J.N. Jenkins
    Ophthalmology, Pharmaceutical Research Network, LLC, Charleston, SC
  • W.C. Stewart
    Ophthalmology, Pharmaceutical Research Network, LLC, Charleston, SC
  • Footnotes
    Commercial Relationships  A.G. Konstas, Merck, Alcon, Allergan, Pfizer, F; S. Lake, None; A.I. Economou, None; K. Kaltsos, None; J.N. Jenkins, None; W.C. Stewart, Merck, Pfizer, Alcon, F; Merck, Pfizer, Alcon, R.
  • Footnotes
    Support  This study was supported in part with an unrestricted grant by Pfizer, Inc., New York, NY.
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 442. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A.G. Konstas, S. Lake, A.I. Economou, K. Kaltsos, J.N. Jenkins, W.C. Stewart; 24–Hour Control With the Latanoprost/Timolol Maleate Fixed Combination versus Timolol Maleate . Invest. Ophthalmol. Vis. Sci. 2006;47(13):442.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate 24–hour intraocular pressure control with evening dosing of the latanoprost/timolol maleate fixed combination versus timolol maleate in patients with primary open–angle glaucoma.

Methods: : A two–period, observer–masked, crossover, randomized, active–controlled comparison. After an appropriate 4–6 week medicine free period, qualified patients were randomized to either placebo dosed in the morning with the latanoprost/timolol maleate fixed combination dosed in the evening or timolol dosed twice daily for eight weeks. Patients were then switched to the opposite treatment for eight weeks. At baseline and at the end of each treatment period patients underwent intraocular pressure measurements at 06:00, 10:00, 14:00, 18:00, 22:00 and 02:00 hours.

Results: : Both treatments reduced the intraocular pressure from untreated baseline at each time point and for the 24–hour curve (P < 0.0001). When treatments were compared, the latanoprost/timolol maleate fixed combination decreased the intraocular pressure more than timolol maleate at each time point and for the 24–hour curve (2.9 mm Hg), as well as provided a lower absolute intraocular pressure at each time point and for the 24–hour curve (P < 0.0001). Several side effects were observed more often with the latanoprost/timolol maleate fixed combination including: ocular stinging (P = 0.05), conjunctival hyperemia (P = 0.02) and ocular itching (P = 0.04).

Conclusions: : This study suggests that evening dosing of the latanoprost/timolol maleate fixed combination provides better intraocular pressure control than timolol maleate over 24–hours, and demonstrates a narrower range of intraocular pressure fluctuation, in primary open–angle glaucoma patients.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • intraocular pressure 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×